| 2024年中报 | 2023年年报 | 2023年中报 | 2022年年报 | 2022年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 销售商品(元) | 1,304,669,628.08 | - | 808,075,290.81 | - | 376,009,837.38 |
| 抗体药物(元) | - | 103,401,862.16 | - | 19,657,499.50 | - |
| 重组蛋白药物(元) | - | 1,780,050,846.01 | - | 1,003,519,179.15 | - |
| 疫苗(元) | - | 3,896,598.23 | - | - | - |
| 营业成本(元) | |||||
| 销售商品(元) | 44,556,380.32 | - | 25,650,038.36 | - | 13,235,871.66 |
| 抗体药物(元) | - | 8,273,238.21 | - | 2,713,655.77 | - |
| 重组蛋白药物(元) | - | 45,968,642.29 | - | 31,162,858.28 | - |
| 疫苗(元) | - | 299,604.03 | - | - | - |
| 毛利(元) | |||||
| 销售商品(元) | 1,260,113,247.76 | - | 782,425,252.45 | - | 362,773,965.72 |
| 抗体药物(元) | - | 95,128,623.95 | - | 16,943,843.73 | - |
| 重组蛋白药物(元) | - | 1,734,082,203.72 | - | 972,356,320.87 | - |
| 疫苗(元) | - | 3,596,994.20 | - | - | - |
| 毛利率(%) | |||||
| 销售商品(%) | 96.58 | - | 96.83 | - | 96.48 |
| 抗体药物(%) | - | 92.00 | - | 86.20 | - |
| 重组蛋白药物(%) | - | 97.42 | - | 96.89 | - |
| 疫苗(%) | - | 92.31 | - | - | - |
| 收入构成(%) | |||||
| 销售商品(%) | 100.00 | - | 100.00 | - | 100.00 |
| 抗体药物(%) | - | 5.48 | - | 1.92 | - |
| 重组蛋白药物(%) | - | 94.31 | - | 98.08 | - |
| 疫苗(%) | - | 0.21 | - | - | - |
| 毛利构成(%) | |||||
| 销售商品(%) | 100.00 | - | 100.00 | - | 100.00 |
| 抗体药物(%) | - | 5.19 | - | 1.71 | - |
| 重组蛋白药物(%) | - | 94.61 | - | 98.29 | - |
| 疫苗(%) | - | 0.20 | - | - | - |